Key Drivers
- High ROE/ROA
- Strong FCF
- Tight working capital
AIAI Summary
Chemed has moved from a reliable, margin‑rich cash compounder to an operationally challenged cash generator where upside now hinges on demonstrable margin stabilization at VITAS (resolution or mitigation of Florida Medicare cap impacts and restored hospital referral mix) and a turnaround in Roto‑Rooter lead quality/pricing rather than just its historical FCF and buybacks. Investors should be cautious and wait for sequential EBITDA improvement, improved hospital admissions mix, reduced paid‑lead dependency, and clarity on the securities investigation before adding meaningfully.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High ROE/ROA
- •Strong FCF
- •Tight working capital
CHE combines high profitability and strong free cash flow with minimal debt but faces tight short-term liquidity and premium valuation driven by large intangibles.
Price Behavior
Key Price Behavior Insights:
- •Lower highs/lows
- •~20% drop
- •Resistance at late‑Feb
Over the last month the stock has formed a clear short-term downtrend, dropping about 20% to a fresh low on 2026-03-20 with the late‑February price cluster now acting as nearby resistance and the 2026-03-20 low as nearest support (break below confirms continuation; reclaim of mid‑March/late‑Feb levels would signal stabilization or a mean‑reversion bounce).
Rapid ~20% decline over last month, increasing short-term oversold/rebound potential
Sentiment & News
Key News Insights:
- •Missed estimates
- •Guidance cut
- •Legal probe
Chemed's weak Q4, lowered 2026 EPS outlook and margin compression drove a roughly 15% share drop, triggered investor outreach and a securities probe while an unrelated Chemtrade transcript was also included in the feed.
The confluence of disappointing results, downward guidance and regulatory scrutiny raises near-term downside risk and volatility for Chemed shares until management restores confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings